Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14799238 | 0.84 | ALDH1A1 (0.72) | MAPTHPGDALDH1A1TDP1POLB | |
| SCHEMBL8395110 | 0.83 | ALDH1A1 (0.50) | MAPTHPGDALDH1A1TDP1POLB | |
| SCHEMBL14667063 | 0.83 | RXFP1 (0.52) | MAPTHPGDALDH1A1TDP1POLB | |
| SCHEMBL8399318 | 0.82 | HSP90AA1 (0.54) | MAPTHPGDALDH1A1POLBMEN1 | |
| SCHEMBL29922173 | 0.81 | ALDH1A1 (0.59) | MAPTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL31391972 | 0.81 | RAB9A (0.53) | MAPTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL476310 | 0.81 | ALDH1A1 (0.59) | MAPTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL3435395 | 0.81 | RAB9A (0.53) | MAPTHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL5248250 | 0.81 | ALDH1A1 (0.72) | MAPTHPGDALDH1A1TDP1POLB | |
| SCHEMBL762026 | 0.80 | ALDH1A1 (0.51) | MAPTHPGDALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2024-10-29 | — | — | US | disclosed |
| CN-111471021-B | Substituted diamino carboxamides and diamino carbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4328223-A2 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals, LLC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-2699553-B1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2023-04-13 | — | — | US | disclosed |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2021-04-22 | — | — | US | disclosed |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2021-02-16 | — | — | US | disclosed |
| CN-111499580-A | Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2020-08-07 | — | — | CN | disclosed |
| CN-111471021-A | Substituted diaminocarboxamides and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | 西格诺药品有限公司 | 2020-07-31 | — | — | CN | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009145856-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | MAPT 1178/4885HPGD 3129/4885ALDH1A1 4344/4885 |
| US-12129237-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPT 3724/4885HPGD 1155/4885ALDH1A1 794/4885 |
| US-20230116093-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | MAPT 3724/4885HPGD 1155/4885ALDH1A1 794/4885 |
| US-20210114992-A1 | SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, HDGF, MAP3K1 | MAPT 3724/4885HPGD 1155/4885ALDH1A1 794/4885 |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | MAPT 4551/4885HPGD 2004/4885ALDH1A1 2316/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | MAPT 4703/4885HPGD 1693/4885ALDH1A1 2657/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | MAPT 246/4885HPGD 2669/4885ALDH1A1 2512/4885 |
| US-11325890-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPT 3724/4885HPGD 1155/4885ALDH1A1 794/4885 |
| US-10919865-B2 | Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith | MAP3K2, HDGF, MAP3K1 | MAPT 3724/4885HPGD 1155/4885ALDH1A1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.